Nifedipine in pregnancy

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 107, Issue 3, 2000, Pages 299-307

  Smith, Patricia ^a   Anthony, John ^b   Johanson, Richard ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; DIAZOXIDE; DIGOXIN; DIHYDRALAZINE; GLUCONATE CALCIUM; HYDRALAZINE; IBUPROFEN; INDOMETACIN; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENYTOIN; PLASMA SUBSTITUTE; PREDNISONE; RITODRINE; TERBUTALINE; THEOPHYLLINE; UTERUS SPASMOLYTIC AGENT;

CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DYSPNEA; FEMALE; FETUS; FETUS DISEASE; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HEPATITIS; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; INTUBATION; LETHARGY; LUNG EDEMA; MATERNAL HYPERTENSION; MUSCLE WEAKNESS; NONHUMAN; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SLOW RELEASE FORMULATION; TERATOGENICITY; THORAX PAIN;

DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; NIFEDIPINE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; VASODILATOR AGENTS;

EID: 0034057748     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2000.tb13222.x     Document Type: Review

References (111)

1. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders 1985; 30: 182–274.
2. Young RC, Smith LA, McLaren MD. T-type and L-type calcium currents in freshly dispersed human uterine smooth muscle cells. T-type and L-type calcium currents in freshly dispersed human uterine smooth muscle cells 1993; 169: 785–792.
3. Singh NB. The mechanism of action of calcium antagonists relative to their clinical applications. The mechanism of action of calcium antagonists relative to their clinical applications 1986; 21: 109–121.
4. Feely J. Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects. Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects 1984; 17: 83–85.
5. Forman A, Gandrup P, Andersson KE, Ulmsten U. Effects of nifedipine on spontaneous and methylergotamine induced activity post partum. Effects of nifedipine on spontaneous and methylergotamine induced activity post partum 1982; 144: 442–448.
6. Maigaard S, Forman A, Andersson KE, Ulmsten U. Comparison of the effects of nicardipine and nifedipine on isolated human myometrium. Comparison of the effects of nicardipine and nifedipine on isolated human myometrium 1983; 16: 354–366.
7. Ulmsten U, Anderssn KE, Forman A. Relaxing effects of nifedipine on the pregnant uterus in vitro and in vivo. Relaxing effects of nifedipine on the pregnant uterus in vitro and in vivo 1978; 52: 536–541.
8. Batra SC, Popper LD. Characterization of membrane calcium channels in nonpregnant and pregnant human uterus. Characterization of membrane calcium channels in nonpregnant and pregnant human uterus 1989; 27: 57–61.
9. Andersson KE, Ingemarsson I, Ulmsten U, Wingerup L. Inhibition of prostaglandin induced uterine activity by nifedipine. Inhibition of prostaglandin induced uterine activity by nifedipine 1979; 86: 175–179.
10. Forman A, Gandrup P, Andersson KE, Ulmsten U. Effects of nifedipine on oxytocin and prostaglandin F2 a induced activity in the postpartum uterus. Effects of nifedipine on oxytocin and prostaglandin F2 a induced activity in the postpartum uterus 1982; 144: 665–670.
11. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Pharmacokinetics and metabolism of nifedipine 1983; 5: 18–24.
12. McAllister RG. Kinetics and dynamics of nifedipine after oral and sublingual doses. Kinetics and dynamics of nifedipine after oral and sublingual doses 1986; 81 (Suppl 6A): 2–5.
13. van Harten J, Burggraaf K, Danhof M, Van Brummelen P, Breimer DD. Negligible sublingual absorption of Nifedipine. Negligible sublingual absorption of Nifedipine 1987; 2: 1363–1365.
14. Ferguson JE, Schutz T, Pershe R, Blaschke T, Stevenson DK. Nifedipine pharmacokinetics during preterm labor tocolysis. Nifedipine pharmacokinetics during preterm labor tocolysis 1989; 161: 1485–1490.
15. Prevost RR, Pharm D, Sherif A, Whybrew DW, Sibai BM. Oral nifedipine: pharmacokinetics in pregnancy induced hypertension. Oral nifedipine: pharmacokinetics in pregnancy induced hypertension 1992; 12: 174–177.
16. Harake B, Gilbert RD, Ashwall S, Power GG. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep 1987; 157: 1003–1008.
17. Blea CW, Barnard JM, Magness RR, Phernetton TM, Hendricks SK. Effect of nifedipine of fetal and maternal hemodynamics and blood gasses in the pregnant ewe. Effect of nifedipine of fetal and maternal hemodynamics and blood gasses in the pregnant ewe 1997; 176: 922–930.
18. Hypertension in pregnancy. In: Redman C, Turnbull A, Chamberlain G, editors. Obstetrics. Edinburgh: Churchill Livingstone, 1989: 515–542.
19. Arias F, Zamora J. Anti hypertensive treatment and pregnancy outcome in patients with mild chronic hypertension. Anti hypertensive treatment and pregnancy outcome in patients with mild chronic hypertension 1979; 53: 489.
20. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients with mild chronic hypertension. Pregnancy outcome in 211 patients with mild chronic hypertension 1983; 61: 571.
21. William MC, Pernoll ML, Biswas MK. Chronic hypertension in pregnancy. Chronic hypertension in pregnancy 1986; 67: 197–205.
22. Curet LB, Olson RW. Evaluation of a program of bed rest in treatment of chronic hypertension in pregnancy. Evaluation of a program of bed rest in treatment of chronic hypertension in pregnancy 1979; 53: 336.
23. Redman CWG, Beilin LJ, Bonnar J. Fetal outcome in trial of antihypertensive treatment in pregnancy. Fetal outcome in trial of antihypertensive treatment in pregnancy 1976; 2: 753–756.
24. Rubin PC, Clark DM, Summer DJ. Placebo controlled trial of anenolol in treatment of pregnancy associated hypertension. Placebo controlled trial of anenolol in treatment of pregnancy associated hypertension 1983; 1: 431–434.
25. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preclampsia. The role of the spiral arteries in the pathogenesis of preclampsia 1972; 1: 177–191.
26. Hays PM, Cruikshank DP, Dunn LJ. Plasma volume determination in normal and pre-eclampsia pregnancies. Plasma volume determination in normal and pre-eclampsia pregnancies 1985; 151: 958–966.
27. Soffronoff EC, Kaufmann BM, Connaughton JF. Intravascular volume determinations and fetal outcome in hypertensive diseases of pregnancy. Intravascular volume determinations and fetal outcome in hypertensive diseases of pregnancy 1977; 127: 4–10.
28. Theunissen IM, Parer JT. Fluid and electrolytes in pregnancy. Fluid and electrolytes in pregnancy 1994; 37: 3–15.
29. Davey DA, Tiltman A, Vercruysse L, Van Assche A, Rees A, Pijenborg R. Placental bed spiral arteries in the hypertension disorders of pregnancy. Placental bed spiral arteries in the hypertension disorders of pregnancy 1991; 98: 648–655.
30. Wang Y, Walsh SW, Kay HH. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preclampsia. Placental lipid peroxides and thromboxane are increased and prostacyclin is decreased in women with preclampsia 1992; 167: 946–949.
31. Nasiell J, Blanck A, Lunell NO, Faxen M. Altered MRNA expression of placental nitric oxide synathase in pregnancies complicated by pre-eclampsia and or intrauterine growth retardation [abstract]. In: Congress Proceedings of the 10th World Congress of the International Society for the Study of Hypertension in Pregnancy, Seattle, Washington, USA, 1996.
32. Rodgers GM, Taylor RN, Roberts JM. Pre-eclampsia is associated with a serum factor ctyotoxic to human endothelial cells. Pre-eclampsia is associated with a serum factor ctyotoxic to human endothelial cells 1988; 159: 908–914.
33. Lyall F, Greer JA. Pre-eclampsia: a mulifaceted vascular disorder or pregnancy. Pre-eclampsia: a mulifaceted vascular disorder or pregnancy 1994; 12: 1339–1345.
34. Redman CWG, Beilen LJ, Bonnar J. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects. Treatment of hypertension in pregnancy with methyldopa: blood pressure control and side effects 1977; 84: 419–426.
35. Wasserstrum N, Kirshon B, Willis RS, Moise KJ, Cotton DB. Quantitive hemodynamic effects of acute volume expansion in severe pre-eclampsia. Quantitive hemodynamic effects of acute volume expansion in severe pre-eclampsia 1989; 73: 546–550.
36. Sehgal NN, Hitt JR. Plasma volume expansion in the treatment of pre-eclampsia. Plasma volume expansion in the treatment of pre-eclampsia 1980; 138: 165–168.
37. Belfort M, Uys P, Dommisse J, Davey DA. Haemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy. Haemodynamic changes in gestational proteinuric hypertension: the effects of rapid volume expansion and vasodilator therapy 1989; 96: 634–641.
38. Kirshon B, Moise K, Cotton DB, Longmire S, Jones M, Tessem J, Joyce T. Role of volume expansion in severe pre-eclampsia. Role of volume expansion in severe pre-eclampsia 1988; 167: 367–371.
39. Goldby FS, Beilen LJ. How an acute rise in arterial pressure damages arterioles. How an acute rise in arterial pressure damages arterioles 1972; 6: 569–584.
40. Johansson B, Strandgaard S, Lassen NA. The pathogenesis of hypertensive encephalopathy. The pathogenesis of hypertensive encephalopathy 1974; 34: 167–171.
41. Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1985–1987. London: HMSO, 1992.
42. Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1988–1990. London: HMSO, 1994.
43. Department of Health. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991–1993. London: HMSO, 1996.
44. Redman CWG. Drugs, hypertension and pregnancy. Prog Obstet Gynaecol 1989; 83–95.
45. British Medical Association. British National Formulary. London: BMA, 1993.
46. Rubin PC. Beta blockers in pregnancy. Beta blockers in pregnancy 1981; 305: 1323.
47. Habib A, McCarthy JS. Effects on the neonate of propranolol administered during pregnancy. Effects on the neonate of propranolol administered during pregnancy 1977; 91: 808.
48. Vink GJ, Moodley J, Philpott RH. Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Effect of dihydralazine on the fetus in the treatment of maternal hypertension 1980; 55: 519–522.
49. Wasserstrum N. Nitropusside in pre-eclampsia. Nitropusside in pre-eclampsia 1991; 18: 79–84.
50. Naden RP, Redman CWG. Anti hypertensive drugs in pregnancy. Symposium on medical disorders during pregnancy. Anti hypertensive drugs in pregnancy. Symposium on medical disorders during pregnancy 1985; 12: 521–538.
51. Sibai BM, Barton JR, Sherif AKL, Sarinoglu C, Mercer BM. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term 1992; 167: 879–884.
52. Ismail AA, Medhat I, Tawfic TA, Kholeif A. Evaluation of calcium-antagonists (nifedipine) in the treatment of pre-eclampsia. Evaluation of calcium-antagonists (nifedipine) in the treatment of pre-eclampsia 1993; 40: 39–43.
53. Jayawardana J, Lekange N. A comparison of nifedipine with methyldopa in pregnancy induced hypertension. A comparison of nifedipine with methyldopa in pregnancy induced hypertension 1994; 39: 87–90.
54. Fenakel K, Fenakel G, Appelman ZVI, Lurie S, Katz ZVI, Shoham Z. Nifedipine in the treatment of severe Preeclampsia. Nifedipine in the treatment of severe Preeclampsia 1991; 77: 331–337.
55. Constantine G, Beevers DG, Reynolds AL, Luesley DM. Nifedipine as a second line antihypertensive drug in pregnancy. Nifedipine as a second line antihypertensive drug in pregnancy 1987; 94: 1136–1142.
56. Norris MC, Rose JC, Dewan DM. Nifedipine or verapamil counteracts hypertension in gravid ewes. Nifedipine or verapamil counteracts hypertension in gravid ewes 1986; 65: 254–258.
57. Walters BNJ, Redman CWG. Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine 1984; 91: 330–336.
58. Visser W, Wallenburg HCS. A comparison between the haemodynamic effects of oral nifedipine and IVI dihydrazine in patients with severe pre-eclampsia. A comparison between the haemodynamic effects of oral nifedipine and IVI dihydrazine in patients with severe pre-eclampsia 1995; 13: 791–795.
59. Jegasothy R, Paranthaman S. Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice. Sublingual nifedipine compared with intravenous hydrallazine in the acute treatment of severe hypertension in pregnancy: potential for use in rural practice 1996; 22: 21–24.
60. Seabe SJ, Moodley J, Becker P. Nifedipine in acute hypertensive emergencies in pregnancy. Nifedipine in acute hypertensive emergencies in pregnancy 1989; 76: 248–250.
61. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy 1997; 157: 1245–1254.
62. Australasian Society for the Study of Hypertension in Pregnancy. Management of hypertension in pregnancy [consensus statement]. Melbourne, Australia, 1993: 1.
63. Connell H, Dalgleish JG, Downing JW. General anaesthesia in mothers with severe preeclampsia/eclampsia. General anaesthesia in mothers with severe preeclampsia/eclampsia 1987; 59: 1375–1380.
64. Puri GD, Batra YK. Effect of nifedipine on cardiovascular responses to laryngoscopy and intubation. Effect of nifedipine on cardiovascular responses to laryngoscopy and intubation 1988; 60: 579–581.
65. Kale SC, Mahajan RP, Jayalakshami TS, Raghavan V, Das B. Nifedipine prevents the pressure response to laryngoscopy and tracheal intubation in patients with coronary artery disease. Nifedipine prevents the pressure response to laryngoscopy and tracheal intubation in patients with coronary artery disease 1988; 43: 495–497.
66. Kumar N, Batra YK, Bala I, Gopalan S. Nifedipine attenuates the hypertensive response to tracheal intubation in pregnancy-induced hypertension. Nifedipine attenuates the hypertensive response to tracheal intubation in pregnancy-induced hypertension 1993; 40: 329–333.
67. Keirse MJNC. Calcium antagonists vs betamimetics in preterm labour. In: Neilson JP, Crowther C, Hodnett ED, Hofmeyr GJ, Keirse MJNC, editors. Pregnancy and Childbirth Module of the Cochrane Database of Systematic Reviews. Oxford: Update Software, Issue 2, 1995.
68. Keirse MJNC. Betamimetic tocolytics in preterm labour. In: Neilson JP, Crowther C, Hodnett ED, Hofmeyr GJ, Keirse MJNC, editors. Pregnancy and Childbirth Module of the Cochrane Database of Systematic Reviews. Oxford: Update Software, Issue 2, 1995.
69. Keirse MJNC. Indomethacin tocolysis in preterm labour. In: Neilson JP, Crowther C, Hodnett ED, Hofmeyr GJ, Keirse MJNC, editors. Pregnancy and Childbirth Module of the Cochrane Database of Systematic Reviews. Oxford: Update Software, Issue 2, 1995.
70. Benedetti TJ. Maternal complications of parenteral beta-sympathomimetic therapy for premature labor. Maternal complications of parenteral beta-sympathomimetic therapy for premature labor 1983; 145: 1–6.
71. Ferguson JE, Dyson DC, Holbrook RH, Schultz T, Stevenson D. Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis 1989; 161: 788–795.
72. Anthony J, Johanson RB, Duley L. Role of magnesium sulphate in seizure prevention in patients with eclampsia and pre-eclampsia. Role of magnesium sulphate in seizure prevention in patients with eclampsia and pre-eclampsia 1996; 15: 188–199.
73. Norton ME, Merrill J, Cooper BAB, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labour. Neonatal complications after the administration of indomethacin for preterm labour 1993; 329: 1602–1607.
74. Tracy TS, Black CD. Ability of nifedipine to prolong parturition in rats. Ability of nifedipine to prolong parturition in rats 1992; 95: 139–144.
75. Abel MH, Hollingsworth M. Comparison of nifedipine and diltiazem with salbutamol for prevention of preterm delivery in the ovariectomized, oestrogen-treated, late pregnant rat. Comparison of nifedipine and diltiazem with salbutamol for prevention of preterm delivery in the ovariectomized, oestrogen-treated, late pregnant rat 1986; 77: 559–568.
76. Gallagher LA, Gautieri RF. Influence of a combination of ritodrine and nifedipine on the isolated rat uterus. Influence of a combination of ritodrine and nifedipine on the isolated rat uterus 1992; 75: 3–18.
77. Golichowski AM, Hathway DR, Fineberg N, Peleg D. Tocolytic and hemodynamic effects of nifedipine in the ewe. Tocolytic and hemodynamic effects of nifedipine in the ewe 1985; 151: 1134–1140.
78. Read MD, Wellby DE. The use of a calcium antagonist (nifedipine) to suppress preterm labour. The use of a calcium antagonist (nifedipine) to suppress preterm labour 1986; 93: 933–937.
79. Kupferminc M, Lessing JB, Yaron Y, Peyser MR. Nifedipine versus ritodrine for supression of preterm labor. Nifedipine versus ritodrine for supression of preterm labor 1993; 100: 1090–1094.
80. Van Dijk KG, Dekker GA, van Geijn HP. Ritrodine and nifedipine as tocolytic agents: a preliminary comparison. Ritrodine and nifedipine as tocolytic agents: a preliminary comparison 1995; 23: 409–415.
81. Bracero LA, Leikin E, Kirshbenbaum N, Tejani N. Comparison of nifedipine and ritodrine for the treatment of preterm labor. Comparison of nifedipine and ritodrine for the treatment of preterm labor 1991; 8: 365–369.
82. Meyer WR, Randal HW, Graves WL. Nifedipine versus ritrodrine for suppressing preterm labor. Nifedipine versus ritrodrine for suppressing preterm labor 1990; 35: 649–653.
83. Ferguson JE, Dyson DC, Stevenson DK. A comparison of tocolysis with nifedipine or ritrodrine: analysis of efficacy and maternal, fetal and neonatal outcome. A comparison of tocolysis with nifedipine or ritrodrine: analysis of efficacy and maternal, fetal and neonatal outcome 1990; 163: 105–111.
84. Smith CS, Woodland MB. Clinical comparison of oral nifedipine and subcutaneous terbutaline for initial tocolysis. Clinical comparison of oral nifedipine and subcutaneous terbutaline for initial tocolysis 1993; 10: 280–284.
85. Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study 1993; 169: 960–964.
86. Papatsonis DNM, van Geijn HP, Ader HJ, Lande FM, Bleker OP, Dekker GA. Nifedipine and ritodrine in the management of preterm labour: a randomised multicenter trial. Nifedipine and ritodrine in the management of preterm labour: a randomised multicenter trial 1997; 2: 230–234.
87. McLaughlin BN, Martin WE, Roberts WL, Wiser JC. Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labour. Comparison of magnesium and nifedipine for primary tocolysis and idiopathic preterm labour 1992; 166: 446.
88. Murray C, Haverkamp AD, Orleans M, Berga S, Pecht D. Nifedipine for treatment of preterm labor: a historic prospective study. Nifedipine for treatment of preterm labor: a historic prospective study 1992; 167: 52–56.
89. Overlack A, Johannes ZG, Ressel C, Muller HM, Stumpe KO. Influence of magnesium on blood pressure and the effect of nifedipine in rats. Influence of magnesium on blood pressure and the effect of nifedipine in rats 1987; 9: 139–143.
90. Thorp JM, Spielman FJ, Valea FA, Payne FG, Mueller RA, Cefalo RC. Nifedipine enhances the cardiac toxicity of magnesium sulphate in the isolated perfused Sprague-Dawley rat heart. Nifedipine enhances the cardiac toxicity of magnesium sulphate in the isolated perfused Sprague-Dawley rat heart 1990; 163: 655–656.
91. Waisman GD, Mayorga LM, Camera MI, Vignolo CA, Martinotti A. Magnesium plus nifedipine: Potentiation of hypotensive effect in preeclampsia. Magnesium plus nifedipine: Potentiation of hypotensive effect in preeclampsia 1988; 159: 308–309.
92. Ben-Ami M, Giladi Y, Shaley E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade 1994; 101: 262–263.
93. Scott W, Snyder MD, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. Neuromuscular blockade with magnesium sulfate and nifedipine 1989; 161: 35–36.
94. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in Pregnancy and Lactation. Baltimore: Williams & Williams, 1990: 450–453.
95. Yoshida T, Kanamori S, Hasegawa Y. Hyperphalangeal bones induced in rat pups by maternal treatment with nifedipine. Hyperphalangeal bones induced in rat pups by maternal treatment with nifedipine 1988; 40: 127–132.
96. Danielsson BR, Danielson M, Rundqvist E, Reiland S. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity 1992; 45: 247–258.
97. Magee LA, Schick B, Donnenfeld AE, Sage S, Conover B, Cook L, McElhatton P, Schmidt MA, Koren G. The safety of calcium channel blockers in human pregnancy: A prospective, multicentre cohort study. The safety of calcium channel blockers in human pregnancy: A prospective, multicentre cohort study 1996; 174: 823–828.
98. Sibai BM. Hypertension in pregnancy. Hypertension in pregnancy 1992; 19: 615–632.
99. Ahokas RA, Sibai BM, Mabie WC, Anderson GD. Nifedipine does not adversely affect uteroplacental blood flow in the hypertensive term pregnant rat. Nifedipine does not adversely affect uteroplacental blood flow in the hypertensive term pregnant rat 1989; 159: 1440–1445.
100. Veille JC, Bossonnette JM, Hohimer AR. The effect of a calcium channel blocker (nifedipine) on uterine blood flow in the pregnant goat. The effect of a calcium channel blocker (nifedipine) on uterine blood flow in the pregnant goat 1986; 154: 1160–1163.
101. Hanretty KP, Whittle MJ, Howie CA, Rubin PC. Effect of nifedipine on doppler flow velocity waveforms in severe pre-eclampsia. Effect of nifedipine on doppler flow velocity waveforms in severe pre-eclampsia 1989; 299: 1205–1206.
102. Duggan PM, McCowan LME, Stewart AW. Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension 1992; 32: 335–338.
103. Morretti MM, Fairlie FM, Akl S, Khoury AD, Sibai BM. The effect of nifedipine therapy on fetal and placental doppler waveforms in preeclampsia remote from term. The effect of nifedipine therapy on fetal and placental doppler waveforms in preeclampsia remote from term 1990; 163: 1844–1848.
104. Lindow SW, Davies N, Davey DA, Smith JA. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy. The effect of sublingual nifedipine on uteroplacental blood flow in hypertensive pregnancy 1988; 95: 1276–1281.
105. Belfort MA, Saade GR, Suresh M, Johnson D, Vedernikov YP. Human umbilical vessels: responses to agents frequently used in obstetric patients. Human umbilical vessels: responses to agents frequently used in obstetric patients 1995; 172: 1395–1403.
106. Pirhonen JP, Erkkola RU, Ekblad UU, Nyman L. Single dose of nifedipine in normotensive pregnancy: nifedipine concentrations, hemodynamic responses, and uterine and fetal flow velocity waveforms. Single dose of nifedipine in normotensive pregnancy: nifedipine concentrations, hemodynamic responses, and uterine and fetal flow velocity waveforms 1990; 76: 807–811.
107. Puzy MS, Ackowic KL, Lindow SW, Gonin R. The effect of nifedipine on umbilical artery waveforms in pregnancies complicated by hypertension. The effect of nifedipine on umbilical artery waveforms in pregnancies complicated by hypertension 1991; 79: 192–194.
108. Impey L. Severe hypertension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Severe hypertension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks 1993; 100: 959–961.
109. Hata T, Manabe A, Hatak, Kitao M. Changes in blood velocities of fetal circulation in association with fetal heart rate abnormalities: effect of sublingual administration of nifedipine. Changes in blood velocities of fetal circulation in association with fetal heart rate abnormalities: effect of sublingual administration of nifedipine 1995; 12: 80–81.
110. Lurie S, Fenakel K, Friedman A. Effect of nifedipine on fetal heart rate in the treatment of severe pregnancy-induced hypertension. Effect of nifedipine on fetal heart rate in the treatment of severe pregnancy-induced hypertension 1990; 7: 285–286.
111. Mari G, Kirshon B, Moise KJ, Lee W, Cotton DB. Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor 1989; 161: 1514–1518.